Advanced search
Publication Cover
Future Neurology Volume 1, 2006 - Issue 4
Submit an article Journal homepage
37
Views
0
CrossRef citations to date
0
Altmetric
Review

Interleukin-1 As a Therapeutic Target in Acute Brain Injury

Johann R Selvarajaha The University of Manchester, Faculty of Life Sciences, Manchester, UK. Tel.:+44 161 275 5744; [email protected]Correspondence[email protected]
,
Adrian Parry-Jonesb The University of Manchester, Faculty of Life Sciences, Manchester, UK. Tel.:44 161 275 5744; [email protected]
,
Catherine J McMahonc The University of Manchester, School of Medicine, Faculty of Medicine & Human Sciences, Manchester, UK. Tel.:+44 161 206 5586; [email protected]
&
Nancy J Rothwelld The University of Manchester, Faculty of Life Science, Manchester, UKTel.:+44 161 275 5744;[email protected]
Pages 417-427 | Published online: 25 Jul 2006

Bibliography

  • Oppenheim JJ : Cytokines: past, present, and future.Int. J. Hematol.74,3–8 (2001).
  • Dinarello CA : Biologic basis for interleukin-1 in disease.Blood87,2095–2147 (1996).
  • Gabay C , SmithMF, EidlenD, ArendWP: Interleukin-1 receptor antagonist (IL-1RA) is an acute-phase protein.J. Clin. Invest.99,2930–2940 (1997).
  • Boutin H , KimberI, RothwellNJ, Pinteaux E: The expanding interleukin-1 family and its receptors: do alternative IL-1 receptor/signaling pathways exist in the brain? Mol. Neurobiol.27,239–248 (2003).
  • Vitkovic L , BockaertJ, JacqueC: ‘Inflammatory‘ cytokines: neuromodulators in normal brain?J. Neurochem.74,457–471 (2000).
  • Allan SM , TyrrellPJ, RothwellNJ: Interleukin-1 and neuronal injury.Nat. Rev. Immunol.5,629–640 (2005).
  • Allan SM , RothwellNJ: Cytokines and acute neurodegeneration.Nat. Rev. Neurosci.2,734–744 (2001).
  • Buttini M , SauterA, BoddekeHW: Induction of interleukin-1β mRNA after focal cerebral ischemia in the rat.Brain Res. Mol. Brain Res.23,126–134 (1994).
  • Davies CA , LoddickSA, ToulmondS, StroemerRP, HuntJ, RothwellNJ: The progression and topographic distribution of interleukin-1β expression after permanent middle cerebral artery occlusion in the rat.J. Cereb. Blood Flow Metab.19,87–98 (1999).
  • Stroemer RP , RothwellNJ: Exacerbation of ischemic brain damage by localized striatal injection of interleukin-1β in the rat.J. Cereb. Blood Flow Metab.18,833–839 (1998).
  • Friedlander RM , GagliardiniV, HaraH et al.: Expression of a dominant negative mutant of interleukin-1β converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J. Exp. Med.185,933–940 (1997).
  • Loddick SA , MacKenzieA, RothwellNJ: An ICE inhibitor, z-VAD-DCB attenuates ischemic brain damage in the rat.Neuroreport7,1465–1468 (1996).
  • Relton JK , RothwellNJ: Interleukin-1 receptor antagonist inhibits ischemic and excitotoxic neuronal damage in the rat.Brain Res. Bull.29,243–246 (1992).
  • Relton JK , BeckeyVE, HansonWL, WhalleyET: CP-0597, a selective bradykinin B2 receptor antagonist, inhibits brain injury in a rat model of reversible middle cerebral artery occlusion.Stroke28,1430–1436 (1997).
  • Betz AL , YangGY, DavidsonBL: Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain.J. Cereb. Blood Flow Metab.15,547–551 (1995).
  • Loddick SA , WongML, BongiornoPB, Gold PW, Licinio J, Rothwell NJ: Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochem. Bioph. Res. Co.234(1) 211–215 (1997).
  • Boutin H , LeFeuvreRA, HoraiR, AsanoM, IwakuraY, RothwellNJ: Role of IL-1α and IL-1β in ischemic brain damage.J. Neurosci.21,5528–5534 (2001).
  • Yamasaki Y , MatsuuraN, ShozuharaH, OnoderaH, ItoyamaY, KogureK: Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats.Stroke26,676–680 (1995).
  • Mulcahy NJ , RossJ, RothwellNJ, Loddick SA: Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischemia in the rat. Br. J. Pharmacol.140,471–476 (2003).
  • Pinteaux E , RothwellNJ, BoutinH: Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1RA) are mediated by glia.Glia53(5),551–556 (2006).
  • Hagberg H , GillandE, BonaEet al.: Enhanced expression of interleukin (IL)-1 and IL-6 messenger RNA and bioactive protein after hypoxia–ischemia in neonatal rats.Pediatr. Res.40,603–609 (1996).
  • Hedtjarn M , LeverinAL, ErikssonK, BlomgrenK, MallardC, HagbergH: Interleukin-18 involvement in hypoxic–ischemic brain injury.J. Neurosci.22,5910–5919 (2002).
  • Hu X , Nesic-TaylorO, QiuJet al.: Activation of nuclear factor-κB signaling pathway by interleukin-1 after hypoxia/ischemia in neonatal rat hippocampus and cortex.J. Neurochem.93(1),26–37 (2005).
  • Martin D , ChinookoswongN, MillerG: The interleukin-1 receptor antagonist (rh-IL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia.Exp. Neurol.130,362–367 (1994).
  • Lazovic J , BasuA, LinHWet al.: Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection.Stroke36(10),2226–2231 (2005).
  • Basu A , LazovicJ, KradyJK et al.: Interleukin-1 and the interleukin-1 type 1 receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury. J. Cereb. Blood Flow Metab.25,17–29 (2005).
  • Touzani O , BoutinH, LeFeuvreRet al.: Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type 1 receptor.J. Neurosci.22,38–43 (2002).
  • Ginsberg MD , BustoR: Combating hyperthermia in acute stroke: a significant clinical concern.Stroke29,529–534 (1998).
  • Grohn OHJ , KettunenMI, MakelaHI et al.: Early detection of irreversible cerebral ischemia in the rat using dispersion of the magnetic resonance imaging relaxation time, T1rho. J. Cereb. Blood Flow Metab.20,1457–1466 (2000).
  • Hasegawa Y , LatourLL, SotakCH, DardzinskiBJ, FisherM: Temperature dependent change of apparent diffusion coefficient of water in normal and ischemic brain of rats.J. Cereb. Blood Flow Metab.14,383–390 (1994).
  • Bernard SA , GrayTW, BuistMDet al.: Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia.N. Engl. J. Med.346,557–563 (2002).
  • Hypothermia After Cardiac Arrest Study Group: Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N. Engl. J. Med.346,549–556 (2002).
  • Shankaran S , LaptookAR, EhrenkranzRA et al.: Whole-body hypothermia for neonates with hypoxic–ischemic encephalopathy. N. Engl. J. Med.353,1574–1584 (2005).
  • Sutcliffe IT , SmithHA, StanimirovicD, HutchisonJS: Effects of moderate hypothermia on IL-1β-induced leukocyte rolling and adhesion in pial microcirculation of mice and on proinflammatory gene expression in human cerebral endothelial cells.J. Cereb. Blood Flow Metab.21,1310–1319 (2001).
  • Maher CO , AndersonRE, MartinHS, McClellandRL, MeyerFB: Interleukin-1β and adverse effects on cerebral blood flow during long-term global hypoperfusion.J. Neurosurg.99,907–912 (2003).
  • Emerich DF , DeanRL III, Bartus RT: The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct? Exp. Neurol.173,168–181 (2002).
  • Masada T , HuaY, XiG, YangGY, HoffJT, KeepRF: Attenuation of intracerebral hemorrhage and thrombin-induced brain edema by overexpression of interleukin-1 receptor antagonist.J. Neurosurg.95,680–686 (2001).
  • Szymanska A , BiernaskieJ, Laidley D, Granter-Button S, Corbett D: Minocycline and intracerebral hemorrhage: influence of injury severity and delay to treatment. Exp. Neurol.197(1),189–196 (2006).
  • Um JY , JeongHJ, ParkRK, HongSH, Kim HM: Aspects of gene polymorphisms in cerebral infarction: inflammatory cytokines. Cell Mol. Life Sci.62,824–833 (2005).
  • Tarkowski E , RosengrenL, BlomstrandC et al: Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke26,1393–1398 (1995).
  • Tarkowski E , RosengrenL, BlomstrandC, JensenC, EkholmS, TarkowskiA: Intrathecal expression of proteins regulating apoptosis in acute stroke.Stroke30,321–327 (1999).
  • Zaremba J , SkrobanskiP, LosyJ: Tumor necrosis factor-α is increased in the cerebrospinal fluid and serum of ischemic stroke patients and correlates with the volume of evolving brain infarct.Biomed. Pharmacother.55,258–263 (2001).
  • Kostulas N , PelidouSH, KivisakkP, Kostulas V, Link H: Increased IL-1β, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke30,2174–2179 (1999).
  • Beamer NB , CoullBM, ClarkWM, Hazel JS, Silberger JR: Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann. Neurol.37,800–805 (1995).
  • Beamer NB , CoullBM, ClarkWM, Briley DP, Wynn M, Sexton G: Persistent inflammatory response in stroke survivors. Neurology50,1722–1728 (1998).
  • Leira R , DavalosA, SilvaY et al.: Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology63,461–467 (2004).
  • Pawlikowska L , TranMN, AchrolAS et al.: Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. Stroke35,2294–2300 (2004).
  • Emsley HC , SmithCJ, GeorgiouRF et al.: A randomised Phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry76,1366–1372 (2005).
  • De Simoni MG , PeregoC, RavizzaT et al.: Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur. J. Neurosci.12,2623–2633 (2000).
  • Eriksson C , Van Dam AM, Lucassen PJ, Bol JG, Winblad B, Schultzberg M: Immunohistochemical localization of interleukin-1β, interleukin-1 receptor antagonist and interleukin-1β converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid. Neuroscience93,915–930 (1999).
  • Nishiyori A , MinamiM, TakamiS, Satoh M: Type 2 interleukin-1 receptor mRNA is induced by kainic acid in the rat brain. Brain Res. Mol. Brain Res.50(1-2),237–245 (1997).
  • Ravizza T , VezzaniA: Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1 receptor type 1 in the rat limbic system.Neuroscience137,301–308 (2006).
  • Vezzani A , ContiM, DeLA et al.: Interleukin-1β immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J. Neurosci.19,5054–5065 (1999).
  • Vezzani A , MonetaD, ContiM et al.: Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc. Natl Acad. Sci. USA97,11534–11539 (2000).
  • Ravizza T , BalossoS, LucasSM, AllanS, VezzaniA: Pharmacological inhibition of caspase-1 or p38 MAP kinase phosphorylation potently inhibit seizures in rodents. Presented at:Society for Neuroscience, CA, USA, 906.17 (2004).
  • Dube C , VezzaniA, BehrensM, BartfaiT, BaramTZ: Interleukin-1β contributes to the generation of experimental febrile seizures.Ann. Neurol.57(1),152–155 (2005).
  • Benveniste EN : Cytokine actions in the central nervous system.Cytokine Growth F. R.9(3/4),259–275 (1998).
  • Vezzani A , MonetaD, RichichiC, Perego C, De Simoni MG: Functional role of proinflammatory and anti-inflammatory cytokines in seizures. In: Recent Advances in Epilepsy Research. Binder DK, Scharfman HE (Eds). Kluwer Academic/Plenum Publishers place, NY, USA (2004).
  • Allan SM , ParkerLC, CollinsB, DaviesR, LuheshiGN, RothwellNJ: Cortical cell death induced by IL-1 is mediated via actions in the hypothalamus of the rat.Proc. Natl Acad. Sci. USA97,5580–5585 (2000).
  • Patel HC , RossFM, HeenanLE, Davies RE, Rothwell NJ, Allan SM: Neurodegenerative actions of interleukin-1 in the rat brain are mediated through increases in seizure activity. J. Neurosci. Res.83(3),385–391 (2006).
  • Virta M , HurmeM, HelminenM: Increased frequency of interleukin-1β (-511) allele 2 in febrile seizures.Pediatr. Neurol.26,192–195 (2002).
  • Kanemoto K , KawasakiJ, YuasaS et al.: Increased frequency of interleukin-1β-511T allele in patients with temporal lobe epilepsy, hippocampal sclerosis, and prolonged febrile convulsion. Epilepsia44,796–799 (2003).
  • Lahat E , LivneM, BarrJ, KatzY: Interleukin-1β levels in serum and cerebrospinal fluid of children with febrile seizures.Pediatr. Neurol.17,34–36 (1997).
  • Tutuncuoglu S , KutukculerN, KepeL, CokerC, BerdeliA, TekgulH: Proinflammatory cytokines, prostaglandins and zinc in febrile convulsions.Pediatr. Int.43,235–239 (2001).
  • Virta M , HurmeM, HelminenM: Increased plasma levels of pro- and anti-inflammatory cytokines in patients with febrile seizures.Epilepsia43,920–923 (2003).
  • Ichiyama T , NishikawaM, YoshitomiT, HayashiT, FurukawaS: Tumor necrosis factor-α, interleukin-1β, and interleukin-6 in cerebrospinal fluid from children with prolonged febrile seizures. Comparison with acute encephalitis/encephalopathy.Neurology50,407–411 (1998).
  • Peltola J , PalmioJ, KorhonenLet al.: Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic–clonic seizures.Epilepsy Res.41,205–211 (2000).
  • Peltola J , LaaksonenJ, HaapalaAM, Hurme M, Rainesalo S, Keranen T: Indicators of inflammation after recent tonic–clonic epileptic seizures correlate with plasma interleukin-6 levels. Seizure11,44–46 (2002).
  • Lehtimaki KA , KeranenT, HuhtalaH et al.: Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration.J. Neuroimmunol.152,121–125 (2004).
  • Hulkkonen J , KoskikallioE, RainesaloS, KeranenT, HurmeM, PeltolaJ: The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among therapy resistant epilepsy patients.Epilepsy Res.59,199–205 (2004).
  • Slowik A , BorratynskaA, TurajW et al.: Interleukin 1β-511 C/T polymorphism and risk of aneurismal subarachnoid hemorrhage.J. Neurol. Neurosurg. Psychiatry77(2),279–280 (2006).
  • Kikuchi T , OkudaY, KaitoN, AbeT: Cytokine production in cerebrospinal fluid after subarachnoid hemorrhage.Neurol. Res.17,106–108 (1995).
  • Takizawa T , TadaT, KitazawaK et al.: Inflammatory cytokine cascade released by leukocytes in cerebrospinal fluid after subarachnoid hemorrhage. Neurol. Res.23,724–730 (2001).
  • Mathiesen T , EdnerG, UlfarssonE, AnderssonB: Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor-α following subarachnoid hemorrhage.J. Neurosurg.87,215–220 (1997).
  • Fassbender K , HodappB, RossolS et al.: Inflammatory cytokines in subarachnoid hemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J. Neurol. Neurosurg. Psychiatry70,534–537 (2001).
  • Kwon KY , JeonBC: Cytokine levels in cerebrospinal fluid and delayed ischemic deficits in patients with aneurysmal subarachnoid hemorrhage.J. Korean Med. Sci.16,774–780 (2001).
  • Osuka K , SuzukiY, TanazawaT et al.: Interleukin-6 and development of vasospasm after subarachnoid hemorrhage. Acta Neurochir. Suppl. (Wien)140,943–951 (1998).
  • Hirashima Y , NakamuraS, EndoS, KuwayamaN, NaruseY, TakakuA: Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage.Neurochem. Res.22,1249–1255 (1997).
  • Klemm P , WarnerTD, CorderR, VaneJR: Endothelin-1 mediates coronary vasoconstriction caused by exogenous and endogenous cytokines.J. Cardiovasc. Pharmacol.26(Suppl. 3),S419–S421 (1995).
  • White LR , JuulR, SkaanesKO, AaslyJ: Cytokine enhancement of endothelin ET(B) receptor-mediated contraction in human temporal artery.Eur. J. Pharmacol.406,117–122 (2000).
  • Bramlett HM , DietrichWD: Pathophysiology of cerebral ischemia and brain trauma: similarities and differences.J. Cereb. Blood Flow Metab.24,133–150 (2004).
  • Herx LM , RivestS, YongVW: Central nervous system-initiated inflammation and neurotrophism in trauma: IL-1β is required for the production of ciliary neurotrophic factor.J. Immunol.165,2232–2239 (2000).
  • Lu KT , WangYW, YangJT, YangYL, Chen HI: Effect of interleukin-1 on traumatic brain injury-induced damage to hippocampal neurons. J. Neurotrauma22,885–895 (2005).
  • Knoblach SM , FadenAI: Cortical interleukin-1β elevation after traumatic brain injury in the rat: no effect of two selective antagonists on motor recovery.Neuroci. Lett.289,5–8 (2000).
  • Toulmond S , RothwellNJ: Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat.Brain Res.671,261–266 (1995).
  • Jones NC , PriorMJ, Burden-TehE, MarsdenCA, MorrisPG, MurphyS: Antagonism of the interleukin-1 receptor following traumatic brain injury in the mouse reduces the number of nitric oxide synthase-2-positive cells and improves anatomical and functional outcomes.Eur. J. Neurosci.22,72–78 (2005).
  • Tehranian R , Andell-JonssonS, BeniSM et al.: Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J. Neurotrauma19,939–951 (2002).
  • Morita-Fujimura Y , FujimuraM, Kawase M, Murakami K, Kim GW, Chan PH: Inhibition of interleukin-1β converting enzyme family proteases (caspases) reduces cold injury-induced brain trauma and DNA fragmentation in mice. J. Cereb. Blood Flow Metab.19,634–642 (1999).
  • Holmin S , HojebergB: In situ detection of intracerebral cytokine expression after human brain contusion.Neurosci. Lett.369,108–114 (2004).
  • Hayakata T , ShiozakiT, TasakiO et al.: Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock22,102–107 (2004).
  • Shiozaki T , HayakataT, TasakiO et al.: Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury. Shock23,406–410 (2005).
  • Chiaretti A , GenoveseO, AloeL et al.: Interleukin 1β and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv. Syst.21,185–193 (2005).
  • Rothwell NJ : Interleukin-1 and neuronal injury: mechanisms, modification and therapeutic potential.Brain Behav. Immun.17,152–157 (2003).
  • Cassatella MA : The neutrophil: one of the cellular targets of interleukin-10.Int. J. Clin. Lab. Res.28(3),148–161 (1998).
  • Curran NM , GriffinBD, O‘TooleD, Brady KJ, Fitzgerald SN, Moynagh PN: The synthetic cannabinoid R+WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. J. Biol. Chem.280(43),35797–35806 (2005).
  • Molina-Holgado F , PinteauxE, MooreJD et al.: Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia.J. Neurosci.23(16),6470–6474 (2003).
  • Melcangi RC , Mensah-NyaganAG: Neuroprotective effects of neuroactive steroids in the spinal cord and peripheral nerves.J. Mol. Neurosci.28(1),1–2 (2006).
  • Allan SM : Pragmatic target discovery from novel gene to functionally defined drug target: the interleukin-1 story.Methods in Mol. Med.104,333–346 (2005).
  • Opal SM , FisherCJ Jr, Dhainaut JF et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group. Crit. Care Med.25,1115–1124 (1997).
  • Furst DE , BreedveldFC, KaldenJR et al: Updated consensus statement on biological agents, specifically tumor necrosis factor-α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1RA), for the treatment of rheumatic diseases. Ann. Rheum. Dis.63(2),II2–II12 (2004).
  • Gutierrez EG, Banks WA, Kastin AJ: Blood-borne interleukin-1 receptor antagonist crosses the blood–brain barrier. J. Neuroimmunol.55,153–160 (1994).
  • Perry VH : The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease.Brain. Behav. Immun.18,407–413 (2004).
  • Quagliarello VJ , WispelweyB, LongWJ Jr, Scheld WM: Recombinant human interleukin-1 induces meningitis and blood–brain barrier injury in the rat. Characterization and comparison with tumor necrosis factor. J. Clin. Invest.87,1360–1366 (1991).
  • Mason JL , SuzukiK, ChaplinDD, MatsushimaGK: Interleukin-1β promotes repair of the CNS.J. Neurosci.21,7046–7052 (2001).
  • TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The lenercept multiple sclerosis study group and the University of British Columbia MS/MRI analysis group. Neurology53,457–465 (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.